Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib, Binimetinib, and Nivolumab in MSS BRAF V600E mCRC
NCT04044430Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of encorafenib, binimetinib and nivolumab in metastatic colorectal cancer (mCRC), sponsored by University of California, San Francisco. Primary endpoints: Overall Response Rate up to 3 years and Incidence of treatment-related grade 3 or higher adverse events. Started Aug 2020; status: terminated.
02
Drugs
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04044430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044430.